Patient preferences for treatment of advanced melanoma: impact of comorbidities
Weilandt J, Diehl K, Schaarschmidt ML, Kiecker F, Sasama B, Pronk M, Ohletz J, Koennecke A, Mueller V, Utikal J, Hillen U, Harth W, Peitsch WK (2021)
Publication Type: Journal article
Publication year: 2021
Journal
Book Volume: 19
Pages Range: 58-70
Journal Issue: 1
DOI: 10.1111/ddg.14293
Abstract
Background and objectives: Choice of treatment for advanced melanoma is crucially influenced by comorbidities and patient preferences. Our study aimed to investigate the impact of comorbidities on preferences. Patients and methods: 150 patients with melanoma stage IIC–IV completed a discrete choice experiment to determine preferences for outcome (overall response rate [ORR], 2-year survival, progression-free survival [PFS], time to response [TTR], kind of adverse events [AE], AE-related treatment discontinuation) and process attributes (frequency and route of administration [RoA], frequency of consultations) of systemic melanoma treatments. The impact of comorbidities was assessed by analysis of variance and multivariate regression. Results: Participants with hypertension and other cardiovascular diseases attached significantly greater importance to TTR and RoA than others. Respondents with arthropathy cared more about TTR (β = 0.179, P = 0.047) and RoA, but less about ORR (β = –0.209, P = 0.021). Individuals with diabetes considered AE (β = 0.185, P = 0.039) and frequency of consultations more essential, but ORR less relevant. Those with other malignancies were particularly worried about treatment discontinuation (β = 0.219, P = 0.008), but less about ORR (β = –0.202, P = 0.015). Participants with depression focused more on PFS (β = 0.201, P = 0.025) and less on TTR (β = –0.201, P = 0.023) and RoA (β = –0.167, P = 0.050). Conclusions: Treatment preferences of melanoma patients vary significantly dependent on comorbidities.
Authors with CRIS profile
Involved external institutions
Vivantes - Netzwerk für Gesundheit GmbH
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
How to cite
APA:
Weilandt, J., Diehl, K., Schaarschmidt, M.-L., Kiecker, F., Sasama, B., Pronk, M.,... Peitsch, W.K. (2021). Patient preferences for treatment of advanced melanoma: impact of comorbidities. Journal der Deutschen Dermatologischen Gesellschaft, 19(1), 58-70. https://doi.org/10.1111/ddg.14293
MLA:
Weilandt, Juliane, et al. "Patient preferences for treatment of advanced melanoma: impact of comorbidities." Journal der Deutschen Dermatologischen Gesellschaft 19.1 (2021): 58-70.
BibTeX: Download